Phase I Prognostic Online (PIPO) Tool

NCT07593053 | Completed

• 1 other identifier: PR(AG)675/2020
• Study Type: observational
• Target: 586
• Locations: 1 country
• Sites: 1

Brief Summary

Clinical trials are studies that test new treatments to see if they work and are safe for people with certain illnesses. Phase I clinical trials are the earliest stage of testing, where researchers give a new treatment to a small group of people to see if it's safe and how much of it can be given before causing harmful side effects. Selecting patients for these trials is challenging, especially since most of them have already tried other treatments that didn't work. To make sure patients are not harmed during the trial, researchers need to estimate how long they might live, so they don't give the new treatment to someone who might not live long enough to see if it works. Doctors use a variety of tools to estimate how long a patient might live, but it's not always easy to do. To help with this, researchers have developed a new tool called the Phase I prognostic online (PIPO) tool. It helps estimate how long a patient might live by looking at different factors like age, the type of cancer, and other medical conditions. This tool can help doctors decide if a patient should be included in a clinical trial or not. The researchers plan to test this tool to see how well it works, with the goal of using it in clinical practice to help doctors estimate life expectancy and select patients for clinical trials. This will make it easier for doctors to help their patients get access to new treatments that might help them.

Conditions

Oncology

Outcome Measures

Primary Outcomes (1)

• Overall survival

  overall survival as a continuous variable and 3 months overall survival

  1 year

Study Arms (1)

Patients candidates for Phase 1 trials

Drug: Immune checkpoint inhibitor, targeted agents

Interventions

Immune checkpoint inhibitor, targeted agents DRUG

Immune checkpoint inhibitor, targeted agents

Patients candidates for Phase 1 trials

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Phase 1 patients that will receive IT or targeted agents

You may qualify if:

• \- Participants must have been enrolled in a VHIO phase 1 clinical trial or phase 2 basket trial included in this study.

Sponsors & Collaborators

• Vall d'Hebron Institute of Oncology: lead

Study Sites (1)

Vall d'Hebron Institue of Oncology

Barcelona, Spain

Location

MeSH Terms

Conditions

Neoplasms

Interventions

Immune Checkpoint Inhibitors

Intervention Hierarchy (Ancestors)

Molecular Mechanisms of Pharmacological Action; Pharmacologic Actions; Chemical Actions and Uses; Antineoplastic Agents, Immunological; Antineoplastic Agents; Therapeutic Uses

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 11, 2026
• First Posted: May 18, 2026
• Study Start: February 2, 2023
• Primary Completion: April 30, 2026
• Study Completion: April 30, 2026
• Last Updated: May 22, 2026

Record last verified: 2023-03

Locations

ES (1)